AVE

33.3%

0.2¢ avecho biotechnology limited

Investor Hub Answers, page-44

First 44 Last

Share
Profile

Follow
pakkham

12,361 Posts.

634

12/09/23

20:14

Post #: 69832146
Share

Originally posted by FrankieAlfie: ↑

Hi Paul,
there has been an announcement by BOD that their phase 2B trial for insomnia has had some successful results. They are moving towards a schedule 3 with the TGA. How does this place us? It would seem to be great validation but are we closer to being TGA approved given we are soon to start Phase 3 trials?
thank you
Avecho Biotechnology Limited
ASX:AVE
08:52AM 08/09/2023

Hi Phil,

We read the BOD results with great interest and I did have a number of interested shareholders reach out to ask what we could learn heading into our own study. Although their study failed their primary endpoints, it was validating to see a signal for improved sleep using CBD when compared to placebo, even if only in a post-hoc statistical analysis.

The two items that leapt out to us were the following; dose and powering.

BOD tested 50mg and 100mg versus placebo. Their analysis suggested that 50mg didn't work, whereas there was a signal that 100mg did, ie. you need higher doses of CBD to get improved sleep. We are using 75mg and 150mg on our trial, so we're already using a higher dose. Plus, we have our increased absorption to further increase the amount of drug absorbed. So, we're feeling pretty good that BOD's results show that we've got the dose/product correct.

On the powering side, BOD failed to get statistical significance for their primary endpoint (@ p<0.025). But, using a post-hoc analysis, they saw a subset of patients with statistically signifance changes (p<0.05). The way you increase your chances of statistical significance (assuming no change in effectiveness) is simply by dosing more patients. BOD dosed 208 patients. We are planning on dosing about 540. The increase in statistical power in our study is very large, maximising our chance of success in the primary endpoints (required for TGA approval).

In summary, BODs results appear to show that CBD works for sleep, de-risking our trial (thank you BOD!). They showed that the study ideally needs higher doses of CBD and more patients on study, which is exactly what we had planned.

Cheers,

Paul

Expand

my thoughts about >>
someone push the shares to 0.009>> insiders sold dump mode>> knowing placement was at 0.006??
then sophis dump into o,oo5,, coz they have large amount options to ex 0.012
calculated shot
..cow boys of the west by standart

AVE Price at posting: 0.5¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

DVP

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

MGU

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

GRX

GreenX picks up prospective copper project in Germany

WGX

Westgold sets its sights on top five producer status through merger with Karora

VMT

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Is oil undervalued?

BOE

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

NXG

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

VMS

Venture to sniff out high-grade REE targets at Jupiter project, WA

There are more pages in this discussion • 5 more messages in this thread...

First 44 Last

Add AVE (ASX) to my watchlist

(20min delay)
Last 0.2¢		Change -0.001(33.3%)		Mkt cap ! $6.338M

Open	High	Low	Value	Volume
0.2¢	0.3¢	0.2¢	$16.54K	5.758M

Buyers (Bids)

No.	Vol.	Price($)
59	96791453	0.2¢

Sellers (Offers)

Price($)	Vol.	No.
0.3¢	58594028	16

View Market Depth

No.	Vol.	Price($)
59	96791453	0.002
23	74000508	0.001
0	0	0.000
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.003	58594028	16
0.004	22905524	20
0.005	20469333	10
0.006	20865067	11
0.007	10865221	9

Last trade - 16.10pm 02/08/2024 (20 minute delay)

AVE (ASX) Chart

Investor Hub Answers, page-44

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

GreenX picks up prospective copper project in Germany

Westgold sets its sights on top five producer status through merger with Karora

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Is oil undervalued?

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Venture to sniff out high-grade REE targets at Jupiter project, WA

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Investor Hub Answers, page-44

Top Stories

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

GreenX picks up prospective copper project in Germany

Westgold sets its sights on top five producer status through merger with Karora

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Is oil undervalued?

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Venture to sniff out high-grade REE targets at Jupiter project, WA

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News